Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
US Market

Immix Biopharma, Inc. (IMMX) Stock Price & Analysis

31 Followers

IMMX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.68 - $5.37
Previous Close$3.14
Volume536.00K
Average Volume (3M)1.22M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$16.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.5
Beta0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-2.04
Shares Outstanding13,927,067
R-Squared0.00060
Standard Deviation0.38
10 Day Avg. Volume127,665
30 Day Avg. Volume1,223,757
Price to Book (P/B)2.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-10.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha0.03
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

IMMX FAQ

What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $0.68 and its highest was $5.37 in the past 12 months.
    What is Immix Biopharma, Inc.’s market cap?
    Currently, no data Available
    When is Immix Biopharma, Inc.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Immix Biopharma, Inc.’s earnings last quarter?
    Currently, no data Available
    Is Immix Biopharma, Inc. overvalued?
    According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Immix Biopharma, Inc. pay dividends?
      Immix Biopharma, Inc. does not currently pay dividends.
      What is Immix Biopharma, Inc.’s EPS estimate?
      Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Immix Biopharma, Inc. have?
      Immix Biopharma, Inc. has 13,927,067 shares outstanding.
        What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
        Currently, no hedge funds are holding shares in IMMX

        ---

        Immix Biopharma, Inc. Stock Smart Score

        2
        Underperform
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Technicals

        SMA
        Positive
        20 days / 200 days
        Momentum
        -22.08%
        12-Months-Change

        Fundamentals

        Return on Equity
        -515.22%
        Trailing 12-Months
        Asset Growth
        3412.31%
        Trailing 12-Months
        The Immix Biopharma, Inc. stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
        Learn more about TipRanks Smart Score

        Company Description

        Immix Biopharma, Inc.

        Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation.

        ---

        Forecast EPS vs Actual EPS

        Currently, no data available
        Please return soon. This page is being updated.

        Similar Stocks
        Company
        Price & Change
        Follow
        Aridis Pharmaceuticals
        Catalyst Biosciences
        eFFECTOR Therapeutics
        Metacrine

        Popular Stocks

        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis